{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T18:14:32Z","timestamp":1649182472305},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Public Health Ontario"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The combined measles, mumps, rubella (MMR) and measles, mumps, rubella, and varicella (MMRV) vaccines are part of Ontario\u2019s routine immunization schedule.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess adverse events following immunization (AEFIs) reported in Ontario following administration of MMR and MMRV vaccines between 2012 and 2016.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Reports of AEFIs were extracted from the provincial surveillance database on May 9, 2017. Events were grouped by provincial surveillance definitions. Reporting rates were calculated using provincial population estimates or net doses distributed as the denominator. A serious AEFI is defined as an AEFI that resulted in an in-patient hospitalization or death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 289 AEFIs were reported following administration of MMR (n=246) or MMRV (n=43) vaccines, for annualized reporting rates of 16.6 and 8.8 reports per 100,000 distributed doses, respectively. The highest age-specific reporting rate was in children aged 1 to 3 years for MMR (7.7 per 100,000 population) and children aged 4 to 9 years for MMRV (0.8 per 100,000 population). Systemic reactions were the most frequently reported event category, while rash was the most frequently reported event for both vaccines. There were 22 serious AEFIs, 19 following MMR and 3 following MMRV (1.3 and 0.6 per 100,000 doses distributed, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our assessment found a low reporting rate of adverse events following MMR and MMRV vaccines in Ontario. No safety concerns were identified. Our findings are consistent with the safety profiles of these vaccines. Continued monitoring of vaccine safety is necessary to maintain timely detection of unusual postvaccine events and public confidence in vaccine safety.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pch\/pxz037","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T02:40:27Z","timestamp":1554777627000},"page":"358-364","source":"Crossref","is-referenced-by-count":0,"title":["Assessing safety of Ontario\u2019s publicly funded MMR and MMRV immunization programs, 2012 to 2016"],"prefix":"10.1093","volume":"25","author":[{"given":"Chi Yon","family":"Seo","sequence":"first","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Rashid","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario"},{"name":"ICES, Toronto, Ontario"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Harris","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jody","family":"Stapleton","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario"},{"name":"Trillium Health Partners, Toronto, Ontario"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley L","family":"Deeks","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"2020092023142853200_CIT0001","first-page":"1,2","article-title":"Statement on measles-mumps-rubella-varicella vaccine","volume":"36 DCC-9","author":"National Advisory Committee on Immunization (NACI)","year":"2010","journal-title":"Can Comm Dis Rep"},{"key":"2020092023142853200_CIT0002","author":"Ontario Ministry of Health and Long-Term Care"},{"key":"2020092023142853200_CIT0003","volume-title":"Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Program Questions and Answers for Health Care Providers","author":"Ontario Ministry of Health and Long-Term Care","year":"2011"},{"key":"2020092023142853200_CIT0004","volume-title":"RSO","author":"Immunization of School Pupils Act","year":"1990"},{"key":"2020092023142853200_CIT0005","volume-title":"Canadian Immunization Guide: Part 4 - Active Vaccines: Measles Vaccine [Internet]","year":"2016"},{"key":"2020092023142853200_CIT0006","volume-title":"Information sheet observed rate of vaccine reacitons- Measles, mumps and rubella vaccines [Internet]","year":"2014"},{"key":"2020092023142853200_CIT0007","volume-title":"Product Monograph. M-M-R\u00ae II","author":"Merck Canada Inc","year":"2016"},{"key":"2020092023142853200_CIT0008","volume-title":"Product Monograph. PRIORIX-TETRA\u00ae [Internet]","author":"GlaxoSmithKline Inc","year":"2017"},{"issue":"RR-8","key":"2020092023142853200_CIT0009","first-page":"1","article-title":"Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"47","author":"Watson","year":"1998","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"2020092023142853200_CIT0010","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2009.10.015","article-title":"Thrombocytopenic purpura after measles-mumps-rubella vaccination: A systematic review of the literature and guidance for management","volume":"156","author":"Mantadakis","year":"2010","journal-title":"J Pediatr"},{"key":"2020092023142853200_CIT0011","volume-title":"National Academy of Sciences. Adverse effects of vaccines: Evidence and causality","author":"Stratton","year":"2011"},{"issue":"4","key":"2020092023142853200_CIT0012","doi-asserted-by":"crossref","first-page":"815,812","DOI":"10.1542\/peds.112.4.815","article-title":"Vaccine safety datalink team. Risk of anaphylaxis after vaccination of children and adolescents","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"key":"2020092023142853200_CIT0013","volume-title":"R.S.O. 1990, Chapter H.7","author":"Health Protection and Promotion Act","year":"2014"},{"key":"2020092023142853200_CIT0014","volume-title":"Infectious diseases protocol. Appendix B: Provincial case definitions for reportable diseases. Disease: Adverse events following immunization","author":"Ontario Ministry of Health and Long-Term Care","year":"2015"},{"key":"2020092023142853200_CIT0015","author":"International Conference on Harmonisation","year":"1994"},{"key":"2020092023142853200_CIT0016","author":"International Conference on Harmonisation","year":"2003"},{"issue":"31","key":"2020092023142853200_CIT0017","doi-asserted-by":"crossref","first-page":"5675,5676","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"2020092023142853200_CIT0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.14745\/ccdr.v40is3a02","article-title":"Canadian Adverse Events Following Immunization Surveillance System (CAEFISS): Annual report for vaccines administered in 2012","volume":"40","author":"Law","year":"2014","journal-title":"Can Commun Dis Rep"},{"issue":"9","key":"2020092023142853200_CIT0019","doi-asserted-by":"crossref","first-page":"206","DOI":"10.14745\/ccdr.v44i09a04","article-title":"Vaccine safety surveillance in Canada: Reports to CAEFISS, 2013\u20132016","volume":"44","author":"Ahmadipour","year":"2018","journal-title":"Can Commun Dis Rep"},{"key":"2020092023142853200_CIT0020","volume-title":"Annual report on vaccine safety in Ontario, 2016","author":"Ontario Agency for Health Protection and Promotion (Public Health Ontario)","year":"2017"},{"issue":"9","key":"2020092023142853200_CIT0021","doi-asserted-by":"crossref","first-page":"181","DOI":"10.14745\/ccdr.v42i09a04","article-title":"Assessing vaccine safety within Ontario\u2019s universal influenza immunization program, 2012-2013 to 2014-2015","volume":"42","author":"Harris","year":"2016","journal-title":"Can Commun Dis Rep"},{"issue":"7","key":"2020092023142853200_CIT0022","doi-asserted-by":"crossref","first-page":"1063,1064","DOI":"10.3201\/eid2307.161145","article-title":"Measles outbreak with unique virus genotyping, Ontario, Canada, 2015","volume":"23","author":"Thomas","year":"2017","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"2020092023142853200_CIT0023","doi-asserted-by":"crossref","first-page":"241","DOI":"10.14745\/ccdr.v41i10a04","article-title":"A spot of bother: Why varicella vaccine programs matter","volume":"41","author":"Harris","year":"2015","journal-title":"Can Commun Dis Rep"},{"issue":"1","key":"2020092023142853200_CIT0024","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"issue":"34","key":"2020092023142853200_CIT0025","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","article-title":"Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting","volume":"27","author":"Jacobsen","year":"2009","journal-title":"Vaccine"},{"issue":"11","key":"2020092023142853200_CIT0026","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1503\/cmaj.140078","article-title":"Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: A population-based cohort study","volume":"186","author":"MacDonald","year":"2014","journal-title":"CMAJ"},{"issue":"9","key":"2020092023142853200_CIT0027","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3345\/kjp.2014.57.9.384","article-title":"Febrile seizures","volume":"57","author":"Chung","year":"2014","journal-title":"Korean J Pediatr"},{"issue":"5","key":"2020092023142853200_CIT0028","doi-asserted-by":"crossref","first-page":"809,810","DOI":"10.1542\/peds.2011-3198","article-title":"Measles-containing vaccines and febrile seizures in children age 4 to 6 years","volume":"129","author":"Klein","year":"2012","journal-title":"Pediatrics"},{"issue":"12","key":"2020092023142853200_CIT0029","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/00006454-200012000-00002","article-title":"Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up","volume":"19","author":"Patja","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"14","key":"2020092023142853200_CIT0030","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.vaccine.2016.09.033","article-title":"Kawasaki disease and immunisation: A systematic review","volume":"35","author":"Phuong","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"2020092023142853200_CIT0031","first-page":"1","article-title":"Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS): United States, 1991\u20132001","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"}],"container-title":["Paediatrics &amp; Child Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/pch\/article-pdf\/25\/6\/358\/33774849\/pxz037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/pch\/article-pdf\/25\/6\/358\/33774849\/pxz037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T03:14:41Z","timestamp":1600658081000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pch\/article\/25\/6\/358\/5430505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,4,8]]},"published-print":{"date-parts":[[2020,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/pch\/pxz037","relation":{},"ISSN":["1205-7088","1918-1485"],"issn-type":[{"value":"1205-7088","type":"print"},{"value":"1918-1485","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2019,4,8]]}}}